Evolus, Inc. (EOLS) vs Tilray Brands, Inc. (TLRY)

Evolus, Inc. and Tilray Brands, Inc. are both Drug Manufacturers Specialty & Generic companies. Tilray Brands, Inc. is the larger, with a market value of $603.0M against $519.2M — 1.2× the size. Evolus, Inc. grew revenue faster over the last twelve months: 13.9% against 11.5%. Evolus, Inc. has the higher net margin (−10.9% vs −13.3%) and the lower return on invested capital (−14.5% vs −2.27%). Across the 17 metrics below, Evolus, Inc. leads on 11 and Tilray Brands, Inc. on 6.

Valuation

Metric EOLS TLRY Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 1.66 0.50 2.25
P/B n/m 0.29 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m 48.33 12.29
EV/Sales 2.02 0.66 2.56
Earnings yield (6.52%) (26.15%) (2.99%)
Free cash flow yield (4.17%) (32.87%) 0.00%

Profitability

Metric EOLS TLRY Drug Manufacturers Specialty & Generic median
Gross margin 66.74% 28.45% 53.94%
Operating margin (5.90%) (6.88%) 0.00%
Net margin (10.85%) (13.26%) 0.00%
Free cash flow margin (6.92%) (10.77%) 0.00%
Return on equity 138.57% (7.87%) (0.40%)
Return on assets (14.40%) (5.52%) (3.32%)
Return on invested capital (14.47%) (2.27%) 0.00%

Growth

Metric EOLS TLRY Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 13.87% 11.46% 10.01%
EPS growth (last fiscal year) 1.23% 95.57% —
Revenue growth, 5-year CAGR 39.36% 7.82% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric EOLS TLRY Drug Manufacturers Specialty & Generic median
Debt to equity (5.07) 0.24 0.05
Current ratio 1.70 2.21 2.31
Net debt to EBITDA (4.08) 11.34 0.85

Dividend

Metric EOLS TLRY Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric EOLS TLRY Drug Manufacturers Specialty & Generic median
Market cap 519.16m 602.95m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack